Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Kernal Biologics logo — KernalBio creates mRNA therapies that instruct specific cell...

Kernal Biologics

KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine

Founded 2016 United States Cambridge, United States 22 employees Series A Total: $26.82M Biotechnology, Health and Wellness +1

General Information

Company Name Kernal Biologics
Founded Year 2016
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 22
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Series A
Business Model B2B, D2C
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Kernal Biologics. To contact Kernal Biologics, visit kernalbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kernal Biologics compare?

A PDF of Kernal Biologics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kernal Biologics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kernal Biologics

Kernal Biologics, founded in 2016, is pioneering advancements in the Biotechnology, Health and Wellness, and Pharmaceutical sectors. Based in the United States, the company focuses on developing mRNA therapies that instruct specific cells to manufacture their own medicine, offering potential cures for severe diseases such as cancer.

Building upon expertise from prestigious institutions like MIT and Harvard, alongside significant industry experience from Big Pharma, the Kernal team has previously demonstrated success through a prior biotech venture. The company's scientific credentials and strategic focus align with current market trends, emphasizing innovative therapeutic approaches.

Their latest funding milestone came on 01 October 2025, when the Advanced Research Projects Agency for Health (ARPA-H) invested in the company via a grant. This backing not only underscores Kernal's strategic importance but also highlights its potential for substantial impact within the biotech landscape.

Business keywords: mRNA therapies, cancer treatment, synthetic biology, RNA design, immunotherapy, COVID-19 treatment, drug development, cell-specific medicine, biopharmaceuticals, mRNA space expertise, Biotech innovation, medical research, mRNA technology

Services & Products

In vivo cell programming
Targeted mRNA delivery
AI model guided therapeutics

Target Customers

Cancer patients Patients with autoimmune diseases Healthcare providers Biotech researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
Advanced Research Projects Agency for Health (ARPA-H)
Advanced Research Projects Agency for Health (ARPA-H)
01 Oct 2025
Series A $25.00M 5
Amgen Ventures Civilization Ventures Hummingbird Ventures
Amgen Ventures, Civilization Ventures +3
01 Jul 2022
Early VC $1.69M 1
Outsized Ventures
Outsized Ventures
01 Oct 2020
Seed $130.00K 1
Y Combinator
Y Combinator
01 Jun 2020
Grant Undisclosed 2
Boeing ISS National Lab
Boeing, ISS National Lab
01 Oct 2018
Support Program Undisclosed 1
MassChallenge
MassChallenge
01 May 2018

Kernal Biologics Alternatives & Competitors

View All Alternatives
Kernal Biologics vs
Ethris
Ethris Germany

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe res...

Venture round
34 employees
Biopharma, Biotechnology
Kernal Biologics vs
Fate Therapeutics Inc.
Fate Therapeutics Inc. United States

Transforming the lives of patients with autoimmune diseases and cancer.

227 employees
Biotechnology, Health Care
Kernal Biologics vs
Asylia Therapeutics
Asylia Therapeutics

Innovative therapies reshaping immune responses against autoimmune, cancer, and infectious diseases.

Series A
1 employees
Biotechnology, Health Care
View all alternatives

FAQ About Kernal Biologics

KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine
Kernal Biologics was founded in 2016.
Kernal Biologics is headquartered in Cambridge, United States.
Kernal Biologics operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on mRNA therapies, cancer treatment, synthetic biology and RNA design. Its customers include Cancer patients, Patients with autoimmune diseases and Healthcare providers.
Kernal Biologics has a B2B and D2C business model. Its revenue comes from Licensing and Product Sales.
Kernal Biologics has approximately 22 employees.
Kernal Biologics has completed 6 funding rounds, raising a total of $26.82M. The latest funding stage is Series A.
Kernal Biologics offers: In vivo cell programming, Targeted mRNA delivery, AI model guided therapeutics.
Top alternatives and competitors to Kernal Biologics include Ethris, Fate Therapeutics Inc., Asylia Therapeutics, Granza Bio, Arcellx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kernal Biologics and Ethris are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kernal Biologics, https://bouncewatch.com/company/kernal-biologics, updated 18 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout